Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 1,882 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 1,882 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $18.15, for a total transaction of $34,158.30. Following the transaction, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at $2,638,193.25. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Ivan Hyep also recently made the following trade(s):

• On Monday, November 24th, Ivan Hyep sold 17,795 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.55, for a total value of $330,097.25.
• On Friday, November 21st, Ivan Hyep sold 605 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.15, for a total value of $10,980.75.

Bicara Therapeutics Stock Down 1.9%

Shares of NASDAQ:BCAX opened at $16.42 on Tuesday. The stock has a market capitalization of $899.49 million, a P/E ratio of -7.33 and a beta of -0.79. Bicara Therapeutics Inc. has a 52 week low of $7.80 and a 52 week high of $19.71. The firm has a fifty day simple moving average of $17.47 and a two-hundred day simple moving average of $14.77.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.12). On average, analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on BCAX. BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. HC Wainwright reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Finally, Mizuho raised Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Institutional Trading of Bicara Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Schroder Investment Management Group lifted its stake in shares of Bicara Therapeutics by 921.0% in the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock valued at $3,951,000 after purchasing an additional 383,681 shares during the period. Skandinaviska Enskilda Banken AB publ lifted its stake in Bicara Therapeutics by 160.9% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 99,236 shares of the company’s stock valued at $922,000 after buying an additional 61,201 shares in the last quarter. Artisan Partners Limited Partnership acquired a new stake in shares of Bicara Therapeutics in the second quarter worth approximately $3,742,000. TD Asset Management Inc boosted its stake in Bicara Therapeutics by 71.5% during the 2nd quarter. TD Asset Management Inc now owns 224,538 shares of the company’s stock worth $2,086,000 after purchasing an additional 93,600 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey boosted its position in Bicara Therapeutics by 119.6% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company’s stock worth $75,000 after acquiring an additional 4,417 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.